Rufinamide 200 mg Tablets Recalled for Manufacturing Process Deviation
Aurobindo Pharma USA Inc. is recalling Rufinamide 200 mg tablets (Lot RB2023001A) because a batch was released prior to manufacturing approval. The FDA classified this as a Class II recall.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is classified as High severity because it involves a prescription medication released without proper manufacturing approval, meeting the rubric criterion for risk-of-harm products where injury has not been reported. Although no illnesses or injuries have been reported, the FDA's Class II designation indicates potential for adverse health consequences.
Plain-English summary
Aurobindo Pharma USA Inc. is recalling Rufinamide 200 mg tablets due to manufacturing process deviations. The recalled batch (Lot RB2023001A, expiration 02/2025) was released for distribution prior to receiving manufacturing approval. The FDA classified this as a Class II recall.
The product was distributed nationwide in the United States. Approximately 48 bottles of Rufinamide in 120-count packaging were affected. No illnesses or injuries have been reported in connection with this recall.
The recalled product
- Product
- RUFINAMIDE (RUFINAMIDE)
- Brand
- RUFINAMIDE
- Manufacturer
- Aurobindo Pharma USA Inc.
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: RB2023001A
- Exp 02/2025
UPCs (1)
- 0359651616086
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · RUFINAMIDE
- ModerateGlenmark Rufinamide Tablets Recalled for Manufacturing Process Deviations
FDA (Drugs) · 2025-04-16
- ModerateRufinamide Tablets Recalled Due to Manufacturing Quality Deviation
FDA (Drugs) · 2023-08-30
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27